RELMADA THERAPEUTICS, INC. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Relmada Therapeutics, Inc., a Nevada corporation, on November 25, 2015, reporting events that occurred on November 20, 2015. The filing addresses corporate governance amendments rather than operational or financial performance updates.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to legal and governance matters and contains no financial statements or operational data.
Material Changes
On November 20, 2015, the Board of Directors adopted the Second Amended and Restated Bylaws. Key changes include:
- Quorum Reduction: The quorum required for the annual meeting of stockholders was reduced from a majority to 34% of the voting power of the shares.
- Exclusive Forum: Nevada is established as the exclusive forum for litigation involving the Company, its directors, and shareholders.
- Charter Alignment: Provisions inconsistent with the Company's Charter were amended to ensure the Charter controls under Nevada law.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed beyond the standard legal implications of the bylaw changes.
Key Facts for Investor Verification
- Verify the impact of the reduced 34% quorum requirement on shareholder meeting dynamics.
- Confirm the implications of the Nevada exclusive forum provision for potential shareholder litigation.
- Note that this filing does not reflect any changes in the company's financial position or business operations.